Clinical Trials Directory

Trials / Completed

CompletedNCT01844583

Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib

Study of the Effect of Esomeprazole or Rifampin on the Pharmacokinetics of Alisertib and Evaluation of the Effect of Alisertib on the QTc Interval in Patients With Advanced Solid Tumors or Lymphomas

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
55 (actual)
Sponsor
Millennium Pharmaceuticals, Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to assess the drug-drug interaction (DDI) of either esomeprazole or rifampin on the single-dose PK of alisertib, and to complete an intensive QT study of single and multiple-dose alisertib.

Detailed description

The drug tested in this study is called alisertib. Alisertib is being tested to assess the effect of a proton pump inhibitor and strong metabolic inducer on the PK of a single 50 mg dose of alisertib administered as enteric-coated tablets (ECTs). The study enrolled 55 patients. Participants received either: * Esomeprazole 40 mg and Alisertib 50 mg * Rifampin 600 mg and Alisertib 50 mg All participants were asked to take one tablet of alisertib either once or twice daily in all cycles. In Cycle 2, participants were asked to take alisertib plus either esomeprazole or rifampin. This trial was conducted the United States. The overall time to participate in this study was 10 months. Participants made multiple visits to the clinic plus a final visit, 30 days after receiving their last dose of study drug for a follow-up assessment.

Conditions

Interventions

TypeNameDescription
DRUGAlisertibAlisertib tablets
DRUGEsomeprazoleEsomeprazole capsules
DRUGRifampinRifampin capsules

Timeline

Start date
2013-06-25
Primary completion
2014-08-04
Completion
2016-09-06
First posted
2013-05-01
Last updated
2019-03-25
Results posted
2019-03-25

Locations

7 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01844583. Inclusion in this directory is not an endorsement.